To gain additional insight into the biology and clinical relevance of the different BRAF mutations present in human cancer patients, we investigated the detection rate of oncogenic BRAF mutations (excluding fusions, large structural variants, or copy number variants) across various malignancies using the GuardantINFORMTM database, which contains targeted genomic data from over 160,000 patients diagnosed with advanced or metastatic cancer. This evidence concerns the gene BRAF and metastatic malignant neoplasm.